Kasia Hein-Peters, MD

Kasia Hein-Peters, MD

Based in Las Vegas, Nevada. Working globally.

 

Background:

Kasia is the founder of Abante Scientific (www.abantescientific.com). She is board-certified in AI in Medicine and has been an Innovation 360 Licensed Practitioner since 2023.

Kasia graduated as a medical doctor and completed her residency in psychiatry at the Medical University in Wroclaw, Poland. After working as a clinical psychiatrist in a Teaching Hospital, she joined the pharmaceutical and medical device industry, working at Eli Lilly, Merck (MSD), Novartis, Sanofi, and Terumo BCT. She oversaw the launches of several first-in-class treatments, which profoundly improved the standards of patient care. She has deep experience developing enterprise, portfolio, and brand strategies and creating market conditions for growth through policy, advocacy, and scientific initiatives.

After 25+ years of leadership roles in Fortune 500 companies, Kasia now helps her healthcare, life science, and digital health clients de-risk launching new products, reach strategic goals, achieve sustainable growth, create leading brands, and scale up their organizations by developing innovation capabilities and applying a systematic innovation management process. She increases the odds of successfully bringing health innovations to the market, aiming to improve patient outcomes and organizations’ performance.

In addition, Kasia is an advisor and fractional executive in startup companies, and a mentor in incubators and accelerators.

 

Area of expertise:

  • Innovation management, including capabilities assessment, market forces analysis, scenario planning, ideation sessions and commercialization
  • Enterprise strategy development
  • Brand and portfolio strategy
  • Launch excellence
  • Market development and access

 

Pharmaceutical, biotechnology, medical device, and digital health industries, at global, regional, and country level.

Therapy areas: psychiatry, neurology, ophthalmology, urology, infectious diseases, vaccinology, transfusion medicine, oncology, cell & gene therapy, and diabetes.

 

Contact:

E-mail